Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 1

3(42.9%)

7Total

Phase 2(4)

Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05202327Phase 2Completed

PDC-1421 Treatment in Adult Patients With ADHD

Role: lead

NCT03833206Phase 1Not Yet Recruiting

A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients

Role: lead

NCT02944955Phase 2Not Yet Recruiting

A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Role: lead

NCT02802423Phase 1Not Yet Recruiting

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

Role: lead

NCT02699086Phase 2Completed

A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD)

Role: lead

NCT02395978Phase 2Completed

A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder

Role: lead

NCT01774045Phase 1Completed

A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression

Role: lead

All 7 trials loaded